Literature DB >> 28274028

Ano-Genital Warts and HIV Status- A Clinical Study.

Shashikant Balakrishana Dhumale1, Shimpa Sharma2, Arvind Gulbake3.   

Abstract

INTRODUCTION: Ano-Genital Warts (AGW) like other Sexually Transmitted Diseases (STD) is associated with Human Immunodeficiency Virus (HIV) infection. This study of AGW was done in HIV positive and HIV negative patients. AIM: To study the risk factors and clinical presentations of ano-genital warts in HIV positive and negative patients.
MATERIALS AND METHODS: A comparative, cross-sectional, descriptive study of 25 HIV positive and 25 HIV negative (n=50) AGW patients between 15-60 years of both sex was conducted in Dr. D. Y. Patil Hospital and Research Centre from July 2014 to July 2016.
RESULTS: Significant association of HIV positivity (p<0.05) was observed between age group of 15-30 years and HIV negative status (p<0.05) in age group of 31-45 years. HIV positive status significantly higher in patients with self-admitted multiple sexual partners (p<0.01), homosexuality (p<0.05) and presentation with anal warts (p<0.01). HIV negative status correlated significantly with single sexual partner admission (p<0.01) and hetero-sexuality (p<0.05). Gender did not show significant association with number of sexual partners or HIV positivity. Extra-genital or only genital warts had no association with HIV status. Co-STDs though more in number in ser-positive group, did not show any significant association with HIV positivity (p>0.05). No patient presented with changes of malignancy. Four were adolescents below 19 years. Two patients had atypical presentations of giant condylomata i.e., Buschke-Lowenstein Tumour (BLT).
CONCLUSION: HIV positivity was significantly associated with the risk factors of age below 30 years, homo sexuality and multiple sexual partners. Anal warts were significantly common in HIV positive patients. Four adolescents with AGW underline the need for high risk behaviour counselling. No patient had malignant ano-genital warts. Follow up of these patients with Human Papilloma Virus (HPV) sub-typing is necessary.

Entities:  

Keywords:  Comparison; Immunosuppression; Presentations; Venereal

Year:  2017        PMID: 28274028      PMCID: PMC5324473          DOI: 10.7860/JCDR/2017/24610.9171

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  20 in total

1.  Growth trajectories of sexual risk behavior in adolescence and young adulthood.

Authors:  Stevenson Fergus; Marc A Zimmerman; Cleopatra H Caldwell
Journal:  Am J Public Health       Date:  2007-04-26       Impact factor: 9.308

2.  Extensive development of flat warts as a cutaneous manifestation of immune reconstitution syndrome.

Authors:  Dmitri Iarikov; Wayne Duke; Daniel Skiest
Journal:  AIDS Read       Date:  2008-10

3.  Prevalence of genital warts among sexually transmitted disease clinic patients-sexually transmitted disease surveillance network, United States, January 2010 to December 2011.

Authors:  Eloisa Llata; Mark Stenger; Kyle Bernstein; Sarah Guerry; Roxanne Kerani; River Pugsley; Preeti Pathela; Irina Tabidze; Hillard Weinstock
Journal:  Sex Transm Dis       Date:  2014-02       Impact factor: 2.830

Review 4.  Human papillomavirus anogenital disease in HIV-infected individuals.

Authors:  Peter V Chin-Hong; Joel M Palefsky
Journal:  Dermatol Ther       Date:  2005 Jan-Feb       Impact factor: 2.851

5.  Prevalence of Anal High-Risk Human Papillomavirus Infections Among HIV-Positive and HIV-Negative Men Who Have Sex With Men in Nigeria.

Authors:  Rebecca G Nowak; Patti E Gravitt; Xin He; Sosthenes Ketende; Wuese Dauda; Helen Omuh; William A Blattner; Manhattan E Charurat
Journal:  Sex Transm Dis       Date:  2016-04       Impact factor: 2.830

6.  Prevalence of human papillomavirus and co-existent sexually transmitted infections among female sex workers, men having sex with men and injectable drug abusers from eastern India.

Authors:  Ishita Ghosh; Pramit Ghosh; Alok Chandra Bharti; Ranajit Mandal; Jaydip Biswas; Partha Basu
Journal:  Asian Pac J Cancer Prev       Date:  2012

7.  Prevalence of HPV infection among females in the United States.

Authors:  Eileen F Dunne; Elizabeth R Unger; Maya Sternberg; Geraldine McQuillan; David C Swan; Sonya S Patel; Lauri E Markowitz
Journal:  JAMA       Date:  2007-02-28       Impact factor: 56.272

8.  Prevalence and incidence of sexually transmitted infections among South Indians at increased risk of HIV infection.

Authors:  N Kumarasamy; P Balakrishnan; K K Venkatesh; A K Srikrishnan; A J Cecelia; E Thamburaj; S Solomon; K H Mayer
Journal:  AIDS Patient Care STDS       Date:  2008-08       Impact factor: 5.078

9.  Prevaccination distribution of human papillomavirus types in women attending at cervical cancer screening in Belgium.

Authors:  Marc Arbyn; Ina Benoy; Cindy Simoens; Johannes Bogers; Philippe Beutels; Christophe Depuydt
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-01       Impact factor: 4.254

Review 10.  Contribution of sexually transmitted infections to the sexual transmission of HIV.

Authors:  Helen Ward; Minttu Rönn
Journal:  Curr Opin HIV AIDS       Date:  2010-07       Impact factor: 4.283

View more
  3 in total

Review 1.  The Pathogenesis of Giant Condyloma Acuminatum (Buschke-Lowenstein Tumor): An Overview.

Authors:  Dorota Purzycka-Bohdan; Roman J Nowicki; Florian Herms; Jean-Laurent Casanova; Sébastien Fouéré; Vivien Béziat
Journal:  Int J Mol Sci       Date:  2022-04-20       Impact factor: 6.208

2.  Transgenders are the most vulnerable amongst individuals engaging in receptive anal intercourse: A cross-sectional study from North India.

Authors:  Tanvi Arora; Neelam Wadhwa; Deepika Pandhi; Preeti Diwaker; Vinod K Arora
Journal:  J Family Med Prim Care       Date:  2021-12-27

3.  CD4 Trajectory Models and Onset of Non-AIDS-Defining Anal Genital Warts, Precancer, and Cancer in People Living With HIV Infection-1.

Authors:  Yuanfan Ye; Greer A Burkholder; Howard W Wiener; Stella Aslibekyan; Ashraf Khan; Sadeep Shrestha
Journal:  Sex Transm Dis       Date:  2020-09       Impact factor: 3.868

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.